PD48-02: First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations
Sunday, May 5, 2024 1:10 PM to 1:20 PM · 10 min. (US/Central)
304A
Delete